Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 586 across all filing types
Latest filing 2023-11-27 Regulatory Filings
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements. The text describes the entry into a material definitive agreement between Sutro Biopharma and Vaxcyte, including details about the exercise of an option and the manufacturing rights agreement. It is not a full annual or quarterly report, nor an earnings release or proxy statement. It is a regulatory filing announcing a significant contract event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a full financial report but a detailed regulatory disclosure.
2023-11-27 English
Regulatory Filings 2023
Regulatory Filings
2023-11-22 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 21, 2023, reporting the appointment of a new President and Chief Operating Officer, Jane Chung, including details about her compensation and related arrangements. The key section is Item 5.02, which covers departure or appointment of directors or certain officers. There is no financial data or earnings information, nor is this a report or announcement of financial results. The document is not an annual or quarterly report, nor a proxy statement or voting results. It is a regulatory filing specifically announcing a management change. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (5893 characters) supports it being a full filing rather than a brief announcement or certification.
2023-11-21 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a letter from Sutro Biopharma, Inc. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is a formal correspondence related to a regulatory filing process, specifically about the timing of a registration statement becoming effective. The document does not contain financial statements, management discussion, or detailed report content. It is a regulatory procedural letter, not a financial report or announcement of financial results. The document length is short (1728 characters), and it is clearly a regulatory filing communication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-11-17 English
Regulatory Filings 2023
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement. Due to the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but without meaningful content, it cannot be classified as a financial or corporate report.
2023-11-16 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is a registration statement used by companies to register securities for public offering, often as a shelf registration allowing multiple offerings over time. The text includes details about the company, the types of securities to be offered, and disclaimers about the prospectus and offering process. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication announcement, but a full registration statement.
2023-11-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.